Bill Commons

NJ A 3242

in committee

Requires health benefits coverage of continuous glucose monitoring system for treatment of glycogen storage disease.

New Jersey · 222 · lower

Quick answers

Did NJ A 3242 pass?

Not yet. NJ A 3242 is in committee as of 2026-09-17 and has not come to a final vote. Latest recorded action (2026-09-17): Reported out of Assembly Committee, 2nd Reading

What is NJ A 3242 about?

NJ A 3242 is a bill in the 222 titled “Requires health benefits coverage of continuous glucose monitoring system for treatment of glycogen storage disease.”.

Who sponsors NJ A 3242?

Hutchison, Dan, Donlon, Margie, M.D., Simmons, Heather are the primary sponsors of NJ A 3242, joined by 1 cosponsor.

Introduced
2026-01-13
Latest action
2026-09-17 — Reported out of Assembly Committee, 2nd Reading
Bill type
bill
Last updated
—

Sponsors

  • Hutchison, Danprimary
  • Donlon, Margie, M.D.primary
  • Simmons, Heatherprimary
  • Miller, Cody D.cosponsor

Committees

Not provided by source.

Action timeline

  1. 2026-01-13

    Introduced, Referred to Assembly Financial Institutions and Insurance Committee

    introduction,referral-committee

  2. 2026-02-12

    Reported out of Asm. Comm. with Amendments, and Referred to Assembly Appropriations Committee

    referral-committee

  3. 2026-09-17

    Reported out of Assembly Committee, 2nd Reading

    committee-passage,reading-2

Versions

Documents

Votes

Not provided by source.

Related bills

Official source

Attribution

Data from openstates_api_sync, retrieved 2026-09-18T07:10:43.275953Z

Inspect retained evidence for changes recorded after evidence tracking began:

Session-wide evidence can include changes to other bills:

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NJ&identifier=A 3242. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.

See the methodology page for data sources and limitations.